Process-related impurity
A process-related impurity is an unwanted substance in a final product that comes directly from manufacturing, such as leftover reagents or incorrectly assembled peptide chains. It is different from a substance formed when the product breaks down over time.
Also called: PRI, process impurity
Process-related impurity is a manufacturing byproduct that remains in a final peptide or research chemical after synthesis. These unintended materials are left over from production. Checking impurity levels in a lab report or Certificate of Analysis (CoA) helps judge manufacturing quality and product safety.
Main process-related impurity types and testing context
Process-related impurities include synthesis artifacts like truncated or deleted amino acid sequences, chemical residuals such as leftover solvents or scavengers, unwanted counter-ions like trifluoroacetate (TFA), and biological residues like host cell proteins or DNA. Identifying them helps verify a peptide's purity and composition.
Laboratories use Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) to identify and quantify impurities by weighing each component and determining its molecular structure. Stability-indicating high-performance liquid chromatography (HPLC) helps distinguish impurities created during manufacturing from those that form later during storage, giving a clearer picture of the product's history.
Practical interpretation risks around process-related impurities
- Do not assume process-related impurities are inert; they can carry toxicity, alter biological activity, or trigger immune responses.
- Do not rely on a 98% purity claim without identifying the remaining 2%, as it may contain toxic impurities that a quality report should specify.
- Do not treat high residual TFA or unrelated peptide contamination as minor, as it indicates poor purification and a failure to follow Good Manufacturing Practice (GMP).
- Do not confuse process-related impurities with product-related degradants that form during storage due to time or temperature; a thorough lab report must distinguish both.
Sources
- Related impurities in peptide medicines - PubMed
- Liquid Chromatography-High Resolution Mass Spectrometry for ...
- [PDF] Guidance for Industry- Synthetic Peptides - FDA
- Safety risk management for low molecular weight process‐related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential - PMC
- ICH Topic Q 3 A (R2) Impurities in new Drug Substances
- Identification and accurate quantification of structurally ...
- Q 6 B Specifications: Test Procedures and Acceptance Criteria ...
- draft-guideline-development-manufacture-synthetic ... - EMA
- Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides
- [PDF] Guidance for Industry Q3A Impurities in New Drug Substances - FDA
- Q3B(R) Impurities in New Drug Products (Revision 3) | FDA
- ICH Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological products - Scientific guideline | European Medicines Agency (EMA)
- Guideline on the Development and Manufacture of Synthetic ...
- Concept Paper on the Establishment of a Guideline on the Development and Manufacture of Synthetic Peptides
- Common Deficiencies Associated with Comparative ...
- Regulatory Guidelines for the Analysis of Therapeutic ... - PMC
- A Phase-Appropriate Risk Assessment Strategy in Support of the ...
- A stability-indicating method development and validation for the determination of related substances in novel synthetic decapeptide by HPLC - PubMed